Below is a list of all AbbVie clinical trials in Canada that you or someone you know might be interested in joining. Find what you’re looking for by using the filters to narrow down the results. You can also see the full list of conditions in which AbbVie deals here.
Clinical Trials
This is a multi-center study that explores the relationship between recapture of response with escalation to weekly active drug and trough concentration of the active drug before escalation in patients experiencing lack of response (LOR).
The objective of this study is to evaluate the efficacy and safety of an active drug compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).
The objective of this study is to evaluate the efficacy and safety of an active drug compared to placebo as induction therapy in subjects with moderately and severely active Crohn's disease (CD).
A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of an active drug, an orally administered Janus kinase 1 inhibitor, in adult participants with Crohn's Disease.
The purpose of this study is to evaluate the efficacy and safety of an active drug versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).
The study consists of 3 sub-studies, as follows:
- Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of an active drug versus placebo as maintenance therapy in participants with moderately to
The objective of Study M15-991 is to evaluate the efficacy and safety of an active drug versus
placebo during induction therapy in participants with moderately to severely active CD.
To determine the efficacy and safety of multiple doses of an active drug in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to Immunomodulators or anti-Tumor Necrosis Factor (TNF) therapy
This study will evaluate higher versus standard active drug dosing regimens for induction and maintenance therapy in subjects with moderately to severely active Crohn's Disease and evidence of mucosal ulceration.
This is a registry study to evaluate the long-term safety and effectiveness of an active drug in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight loss, and fever. This study evaluates how safe and effective
To evaluate the real-life effect after 1 year of an active drug treatment on psychological distress/depression symptoms in moderate-to-severe Ulcerative Colitis (UC) patients.
The objective of this study is to evaluate the efficacy and safety of an active drug compared to placebo in inducing clinical remission (per Adapted Mayo score) in participants with moderately to severely active ulcerative colitis (UC).
The purpose of this study is to evaluate safety and efficacy of an active drug in subjects with ulcerative colitis (UC) in subjects who responded to induction treatment with an active drug in a prior AbbVie study of an active drug in UC.
This study
The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of an active drug as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of an
This study is designed to evaluate the long-term safety and efficacy of an active drug in participants with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had loss of response during
This study comprises three sub-studies. The objective of sub-study 1 is to characterize the dose-response, efficacy, and safety of an active drug compared to placebo in inducing clinical remission in order to identify the induction dose of an active drug
To evaluate safety and efficacy of two adalimumab dosing regimens for induction and maintenance (standard and higher dosing) in achieving clinical remission in subjects with moderately to severely active ulcerative colitis.
This is a registry study to evaluate the long-term safety and effectiveness of an active drug in patients with moderately to severely active UC who are treated as recommended in the product label.
Study M15-722 is a Phase 2a study to investigate the efficacy and safety of an active drug in participants with moderate to severe UC who failed prior therapy.
